NI200700120A - Formulacion liposomal de bortezomib (ps-341) - Google Patents
Formulacion liposomal de bortezomib (ps-341)Info
- Publication number
- NI200700120A NI200700120A NI200700120A NI200700120A NI200700120A NI 200700120 A NI200700120 A NI 200700120A NI 200700120 A NI200700120 A NI 200700120A NI 200700120 A NI200700120 A NI 200700120A NI 200700120 A NI200700120 A NI 200700120A
- Authority
- NI
- Nicaragua
- Prior art keywords
- liposomes
- bortezomib
- trapped
- liposomal formulation
- boronic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe una composición de liposoma que comprende liposomas que tienen el compuesto inhibidor proteasome bortezomib de ácido borónico péptido atrapado en los liposomas. El compuesto de ácido borónico está atrapado en los liposomas en la forma de un éster boronato, subsecuente a la interacción con un poliol de liposoma atrapado. En una incorporación, los liposomas tienen una capa externa de cadenas hidrofílicas de polímero y se usan para tratar un tumor sólido en un individuo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62521604P | 2004-11-05 | 2004-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI200700120A true NI200700120A (es) | 2008-05-15 |
Family
ID=35947260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI200700120A NI200700120A (es) | 2004-11-05 | 2007-05-04 | Formulacion liposomal de bortezomib (ps-341) |
Country Status (21)
Country | Link |
---|---|
US (2) | US20060159736A1 (es) |
EP (2) | EP1807053A1 (es) |
JP (2) | JP2008519040A (es) |
KR (2) | KR20070085644A (es) |
CN (2) | CN101094648A (es) |
AR (1) | AR051759A1 (es) |
AU (2) | AU2005304880A1 (es) |
BR (2) | BRPI0517061A (es) |
CA (2) | CA2586348A1 (es) |
CR (1) | CR9168A (es) |
EA (1) | EA200701005A1 (es) |
IL (1) | IL182967A0 (es) |
MX (2) | MX2007005497A (es) |
NI (1) | NI200700120A (es) |
NO (1) | NO20072830L (es) |
NZ (2) | NZ554950A (es) |
PE (1) | PE20061135A1 (es) |
TW (1) | TW200618820A (es) |
UY (1) | UY29191A1 (es) |
WO (2) | WO2006052734A1 (es) |
ZA (1) | ZA200705017B (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932517A3 (en) * | 2006-12-11 | 2008-07-16 | Universiteit Utrecht Holding B.V. | Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
WO2009047639A2 (en) * | 2007-07-23 | 2009-04-16 | Keimyung University Industry Academic Cooperation Foundation | Epicatechin deficient green tea |
PT2178888E (pt) * | 2007-08-06 | 2012-10-04 | Millennium Pharm Inc | Inibidores do proteassoma |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
AU2008288920A1 (en) * | 2007-08-21 | 2009-02-26 | Alza Corporation | Liposome formulations of boronic acid compounds |
WO2009026427A2 (en) * | 2007-08-21 | 2009-02-26 | Alza Corporation | Liposome compositions for in vivo administration of boronic acid compounds |
EA201500431A1 (ru) | 2008-06-17 | 2015-11-30 | Милленниум Фармасьютикалз, Инк. | Соединения боронатного эфира и его фармацевтические составы |
KR100918776B1 (ko) * | 2009-04-20 | 2009-09-24 | 계명대학교 산학협력단 | 폴리에틸렌 글리콜과 갈레이트 카테킨을 이용한 혈당상승 억제 조성물 |
EP2323628B1 (en) | 2008-08-13 | 2022-04-13 | California Institute of Technology | Carrier nanoparticles and related compositions, methods and systems |
NZ602392A (en) * | 2010-03-18 | 2014-03-28 | Innopharma Inc | Stable bortezomib formulations |
US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
ES2789177T3 (es) | 2010-08-10 | 2020-10-26 | Melinta Therapeutics Inc | Derivados de éster del ácido borónico cíclicos, procedimiento para la preparación y usos terapéuticos de los mismos |
IT1403157B1 (it) | 2010-12-01 | 2013-10-04 | Elbi Int Spa | Macchina lavatrice con rilevazione delle vibrazioni della vasca o camera di lavaggio. |
BR112013022170B1 (pt) * | 2011-03-02 | 2022-05-24 | Sensulin, Llc | Composições de vesícula |
CN102784114B (zh) * | 2011-05-14 | 2016-03-02 | 山东新时代药业有限公司 | 一种硼替佐米冻干粉针及其制备方法 |
KR20150095809A (ko) | 2012-12-12 | 2015-08-21 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 암 치료용 조성물 및 방법 |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CA2894891A1 (en) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
US9132097B2 (en) | 2013-03-01 | 2015-09-15 | California Institute Of Technology | Nanoparticles stabilized with nitrophenylboronic acid compositions |
WO2015002078A1 (ja) | 2013-07-03 | 2015-01-08 | 日本化薬株式会社 | ボロン酸化合物の新規製剤 |
EP3102585B1 (en) * | 2014-02-03 | 2021-05-19 | Ohio State Innovation Foundation | Boronic acid esters and pharmaceutical formulations thereof |
EP3139930A4 (en) | 2014-05-05 | 2018-01-17 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
EP3140310B1 (en) | 2014-05-05 | 2019-08-07 | Rempex Pharmaceuticals, Inc. | Synthesis of boronate salts and uses thereof |
CN106459096B (zh) | 2014-05-19 | 2019-03-08 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
US20150335668A1 (en) | 2014-05-20 | 2015-11-26 | Millennium Pharmaceuticals, Inc. | Method for cancer therapy |
CA2952968A1 (en) | 2014-07-01 | 2016-01-07 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
AU2016256979B2 (en) * | 2015-05-04 | 2021-01-28 | Versantis AG | Method for preparing transmembrane pH-gradient vesicles |
CN108135916B (zh) * | 2015-06-19 | 2022-01-28 | 北京科辉智药生物科技有限责任公司 | 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用 |
US10287401B2 (en) | 2015-07-01 | 2019-05-14 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
CN104958768A (zh) * | 2015-07-17 | 2015-10-07 | 中国科学院长春应用化学研究所 | 一种葡聚糖-硼替佐米键合药及其制备方法 |
US11135309B2 (en) * | 2015-08-14 | 2021-10-05 | The Regents Of The University Of California | Poly(vinyl alcohol) nanocarriers |
ES2894251T3 (es) | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos |
US10583083B1 (en) * | 2016-08-10 | 2020-03-10 | Verily Life Sciences Llc | ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages |
CA3040820A1 (en) | 2016-10-20 | 2018-04-26 | Pfizer Inc. | Therapeutic particles with peptide boronic acid or boronate ester compounds and methods of making and using same |
SG11202000593TA (en) * | 2017-07-24 | 2020-02-27 | Pharmosa Biopharm Inc | Liposome compositions comprising weak acid drugs and uses thereof |
CN111212843A (zh) | 2017-10-11 | 2020-05-29 | Qpex生物制药有限公司 | 硼酸衍生物及其合成 |
CN110540547A (zh) * | 2018-05-28 | 2019-12-06 | 秦艳茹 | 一种肽硼酸酯类化合物的合成与用途 |
CN109045272A (zh) * | 2018-08-01 | 2018-12-21 | 厦门市壳聚糖生物科技有限公司 | 一种硼替佐米磷脂复合物及其制备方法与应用 |
WO2021071932A1 (en) * | 2019-10-07 | 2021-04-15 | Cornell University | Antimicrobial and antiviral effects of c2-c7alkyl boronic acids |
US20240173374A1 (en) * | 2021-02-25 | 2024-05-30 | Ohio State Innovation Foundation | Liposomal formulations of boronic acid containing active agents |
CN112915094A (zh) * | 2021-03-26 | 2021-06-08 | 东南大学 | 一种硼替佐米脂质体制剂的制备方法 |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US4885172A (en) * | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
US5047245A (en) * | 1985-07-26 | 1991-09-10 | The Liposome Company, Inc. | Novel composition for targeting, storing and loading of liposomes |
US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5620689A (en) * | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
WO1992002244A1 (en) * | 1990-07-31 | 1992-02-20 | The Liposome Company, Inc. | Accumulation of amino acids and peptides into liposomes |
US5395619A (en) * | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
US6180134B1 (en) * | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5972379A (en) * | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
WO1996032930A1 (en) * | 1995-04-18 | 1996-10-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
US6224903B1 (en) * | 1996-10-11 | 2001-05-01 | Sequus Pharmaceuticals, Inc. | Polymer-lipid conjugate for fusion of target membranes |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
EP0932390A1 (en) * | 1996-10-11 | 1999-08-04 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
CA2269758C (en) * | 1996-10-22 | 2008-01-08 | Hermes Biosciences, Inc. | Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation |
US6831057B2 (en) * | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
US6051251A (en) * | 1997-11-20 | 2000-04-18 | Alza Corporation | Liposome loading method using a boronic acid compound |
WO2000023052A1 (en) * | 1998-09-16 | 2000-04-27 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
HUP0202177A3 (en) * | 1999-07-14 | 2004-05-28 | Alza Corp Mountain View | Neutral lipopolymer and liposomal compositions containing same |
AU1658401A (en) * | 1999-11-19 | 2001-05-30 | Topgene, Inc. | Boron compounds and complexes as anti-inflammatory agents |
FI2251344T4 (fi) * | 2001-01-25 | 2024-04-29 | The United States Of America Represented By The Secretary | Boronihappoyhdisteiden formulointi |
US20060084592A1 (en) * | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
ES2421516T3 (es) * | 2002-11-06 | 2013-09-03 | Dana Farber Cancer Inst Inc | Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341 |
-
2005
- 2005-10-25 TW TW094137236A patent/TW200618820A/zh unknown
- 2005-11-02 PE PE2005001284A patent/PE20061135A1/es not_active Application Discontinuation
- 2005-11-04 MX MX2007005497A patent/MX2007005497A/es unknown
- 2005-11-04 JP JP2007540070A patent/JP2008519040A/ja not_active Withdrawn
- 2005-11-04 EP EP05824137A patent/EP1807053A1/en not_active Withdrawn
- 2005-11-04 JP JP2007540071A patent/JP2008519041A/ja not_active Withdrawn
- 2005-11-04 AU AU2005304880A patent/AU2005304880A1/en not_active Abandoned
- 2005-11-04 NZ NZ554950A patent/NZ554950A/en not_active IP Right Cessation
- 2005-11-04 KR KR1020077012434A patent/KR20070085644A/ko not_active Application Discontinuation
- 2005-11-04 UY UY29191A patent/UY29191A1/es unknown
- 2005-11-04 CA CA002586348A patent/CA2586348A1/en not_active Abandoned
- 2005-11-04 AR ARP050104638A patent/AR051759A1/es unknown
- 2005-11-04 NZ NZ554951A patent/NZ554951A/en not_active IP Right Cessation
- 2005-11-04 MX MX2007005499A patent/MX2007005499A/es unknown
- 2005-11-04 US US11/267,076 patent/US20060159736A1/en not_active Abandoned
- 2005-11-04 KR KR1020077012432A patent/KR20070085642A/ko not_active Application Discontinuation
- 2005-11-04 BR BRPI0517061-3A patent/BRPI0517061A/pt not_active IP Right Cessation
- 2005-11-04 AU AU2005304881A patent/AU2005304881A1/en not_active Abandoned
- 2005-11-04 WO PCT/US2005/039973 patent/WO2006052734A1/en active Application Filing
- 2005-11-04 CN CNA2005800457552A patent/CN101094648A/zh active Pending
- 2005-11-04 CN CNA2005800457618A patent/CN101094649A/zh active Pending
- 2005-11-04 BR BRPI0517668-9A patent/BRPI0517668A/pt not_active IP Right Cessation
- 2005-11-04 WO PCT/US2005/039972 patent/WO2006052733A1/en active Application Filing
- 2005-11-04 EP EP05821699A patent/EP1807052A1/en not_active Withdrawn
- 2005-11-04 EA EA200701005A patent/EA200701005A1/ru unknown
- 2005-11-04 CA CA002586354A patent/CA2586354A1/en not_active Abandoned
- 2005-11-04 US US11/267,794 patent/US20060153907A1/en not_active Abandoned
-
2007
- 2007-05-03 IL IL182967A patent/IL182967A0/en unknown
- 2007-05-04 NI NI200700120A patent/NI200700120A/es unknown
- 2007-06-04 ZA ZA200705017A patent/ZA200705017B/xx unknown
- 2007-06-04 NO NO20072830A patent/NO20072830L/no not_active Application Discontinuation
- 2007-06-05 CR CR9168A patent/CR9168A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2007005499A (es) | 2007-09-21 |
JP2008519041A (ja) | 2008-06-05 |
US20060159736A1 (en) | 2006-07-20 |
AR051759A1 (es) | 2007-02-07 |
EP1807053A1 (en) | 2007-07-18 |
CR9168A (es) | 2008-11-24 |
BRPI0517061A (pt) | 2008-09-30 |
CN101094648A (zh) | 2007-12-26 |
NZ554951A (en) | 2010-12-24 |
EP1807052A1 (en) | 2007-07-18 |
NO20072830L (no) | 2007-07-24 |
TW200618820A (en) | 2006-06-16 |
UY29191A1 (es) | 2006-01-31 |
AU2005304881A1 (en) | 2006-05-18 |
CN101094649A (zh) | 2007-12-26 |
NZ554950A (en) | 2010-12-24 |
EA200701005A1 (ru) | 2007-10-26 |
CA2586348A1 (en) | 2006-05-18 |
US20060153907A1 (en) | 2006-07-13 |
AU2005304880A1 (en) | 2006-05-18 |
ZA200705017B (en) | 2008-09-25 |
KR20070085642A (ko) | 2007-08-27 |
WO2006052733A1 (en) | 2006-05-18 |
BRPI0517668A (pt) | 2008-10-14 |
IL182967A0 (en) | 2007-08-19 |
JP2008519040A (ja) | 2008-06-05 |
CA2586354A1 (en) | 2006-05-18 |
WO2006052734A1 (en) | 2006-05-18 |
PE20061135A1 (es) | 2006-10-20 |
MX2007005497A (es) | 2007-09-21 |
KR20070085644A (ko) | 2007-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI200700120A (es) | Formulacion liposomal de bortezomib (ps-341) | |
ECSP109983A (es) | Formulaciones de liposomas de compuestos de acido boronico | |
Honeywell-Nguyen et al. | Quantitative assessment of the transport of elastic and rigid vesicle components and a model drug from these vesicle formulations into human skin in vivo | |
ES2543977T3 (es) | Sistema terapéutico transdérmico para la administración del principio activo buprenorfina | |
CR11625A (es) | Formulacion de capsula | |
AR033808A1 (es) | Una composicion topica de anestesia local y los parches y los envases que la contienen | |
AR048878A1 (es) | Composiciones topicas de metadona y metodos para usarlas | |
AR052057A1 (es) | Composiciones orales que contienen extractos de rosmarinus y metodos ralacionados | |
AR047986A1 (es) | Composiciones de pelicula | |
ES2626639T3 (es) | Medicamento o composición dermatológica que contiene un extracto peptídico de aguacate destinado al tratamiento y a la prevención del prurito interno | |
CL2012000313A1 (es) | Composición de dosificación de película que comprende una matriz portadora, entre 2-16 mg de buprenorfina, entre 0,5-5 mg de naloxona y un tampón que proporciona un ph local entre 2-4; procedimiento de preparación; uso en el tratamiento de la dependencia de narcóticos en un usuario. | |
AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
CL2008003615A1 (es) | Composicion farmaceutica transmucosal oral que comprende fenilefrina, o una sal de ella, que esta en forma de tiras, de capa bioadhesiva, de liquido para pulverizar, de pastilla , de gel, de capsulas o de tableta; dispositivo portador. | |
PE20130377A1 (es) | Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion | |
AR072685A1 (es) | Composicion topica para el tratamiento de queratosis actinica | |
Morilla et al. | Ultradeformable phospholipid vesicles as a drug delivery system: a review | |
CY1108869T1 (el) | Φωτοσταθεροποιημενα τοπικα σκευασματα κετοπροφαινης που περιεχουν δυο φιλτρα uv | |
CL2011000532A1 (es) | Proceso para la obtencion de un film que comprende la incorporación de agentes antimicrobianos de origen natural en una estructura polimerica a través de un doble proceso de extrusión al material polimérico. | |
ECSP056186A (es) | Composición farmacéutica en forma de hidrogel para administración transdérmica de sustancias activas | |
ES2549910T3 (es) | Procedimiento para la fabricación de material de recubrimiento | |
CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
PE20120956A1 (es) | Composicion farmaceutica que contiene buprenorfina y nalmefeno | |
AR061487A1 (es) | Una composicion farmaceutica en forma de comprimido multicapa de tetraciclina | |
CR8723A (es) | Metodo de formacion de una candela con multiples capas de color desprendibles | |
CR11324A (es) | Formulaciones de liposomas de compuestos de ácido boronico |